A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients
Latest Information Update: 05 Nov 2021
At a glance
- Drugs SHR 0534 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 03 Jan 2017 New trial record